MX2016005396A - Composiciones para administracion oral de acido zoledronico o compuestos relacionados para tratar enfermedades. - Google Patents

Composiciones para administracion oral de acido zoledronico o compuestos relacionados para tratar enfermedades.

Info

Publication number
MX2016005396A
MX2016005396A MX2016005396A MX2016005396A MX2016005396A MX 2016005396 A MX2016005396 A MX 2016005396A MX 2016005396 A MX2016005396 A MX 2016005396A MX 2016005396 A MX2016005396 A MX 2016005396A MX 2016005396 A MX2016005396 A MX 2016005396A
Authority
MX
Mexico
Prior art keywords
zoledronic acid
compositions
oral administration
related compounds
treating disease
Prior art date
Application number
MX2016005396A
Other languages
English (en)
Spanish (es)
Inventor
Tabuteau Herriot
Original Assignee
Antecip Bioventures Ii Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/063,979 external-priority patent/US8802658B2/en
Application filed by Antecip Bioventures Ii Llc filed Critical Antecip Bioventures Ii Llc
Publication of MX2016005396A publication Critical patent/MX2016005396A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2016005396A 2013-10-25 2014-08-08 Composiciones para administracion oral de acido zoledronico o compuestos relacionados para tratar enfermedades. MX2016005396A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/063,979 US8802658B2 (en) 2012-05-14 2013-10-25 Compositions for oral administration of zoledronic acid or related compounds for treating disease
US14/279,241 US20140249317A1 (en) 2012-05-14 2014-05-15 Compositions for oral administration of zoledronic acid or related compounds for treating disease
PCT/US2014/050427 WO2015060924A1 (en) 2013-10-25 2014-08-08 Compositions for oral administration of zoledronic acid or related compounds for treating disease

Publications (1)

Publication Number Publication Date
MX2016005396A true MX2016005396A (es) 2017-03-01

Family

ID=52993341

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005396A MX2016005396A (es) 2013-10-25 2014-08-08 Composiciones para administracion oral de acido zoledronico o compuestos relacionados para tratar enfermedades.

Country Status (12)

Country Link
EP (1) EP3060220A4 (ja)
JP (6) JP6166471B2 (ja)
KR (3) KR101975687B1 (ja)
CN (2) CN108434154A (ja)
AU (2) AU2014340649C1 (ja)
CA (1) CA2928350C (ja)
HK (1) HK1257400A1 (ja)
IL (2) IL245287A0 (ja)
MX (1) MX2016005396A (ja)
MY (1) MY176246A (ja)
SG (3) SG10201800001VA (ja)
WO (1) WO2015060924A1 (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10016445B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10413561B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US10493085B2 (en) 2012-05-14 2019-12-03 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US9956238B2 (en) 2014-05-15 2018-05-01 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9999629B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10350227B2 (en) 2012-05-14 2019-07-16 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US11654152B2 (en) 2012-05-14 2023-05-23 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US10413560B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US10463682B2 (en) 2012-05-14 2019-11-05 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating low back pain
CN108434154A (zh) * 2013-10-25 2018-08-24 安泰赛普生物风投二代有限责任公司 用于治疗疾病的唑来膦酸或相关化合物的经口施用组合物
CN109891021B (zh) 2016-10-28 2022-04-12 三菱化学株式会社 碳纤维用上浆剂、碳纤维用上浆剂的水分散液、和附着有上浆剂的碳纤维束

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
JP2004528340A (ja) * 2001-05-02 2004-09-16 ノバルティス アクチエンゲゼルシャフト ビスホスホネートの医薬的使用
US7875597B2 (en) * 2002-07-24 2011-01-25 New York University Treatment of spinal mechanical pain
EP1567533B1 (en) * 2003-07-03 2009-03-11 Teva Pharmaceutical Industries Ltd. Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
AR046773A1 (es) * 2003-12-23 2005-12-21 Novartis Ag Formulaciones farmaceuticas de bisfosfonatos
SI2459176T1 (en) * 2009-07-31 2018-01-31 Gruenenthal Gmbh Crystallization process and bioavailability
LT2531200T (lt) * 2010-02-06 2017-09-25 Grünenthal GmbH Kristalizacijos būdas ir bioprieinamumas
US9340565B2 (en) * 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
US20130303488A1 (en) * 2012-05-14 2013-11-14 Herriot Tabuteau Compositions Comprising Zoledronic Acid or Related Compounds for Treatment of Complex Regional Pain Syndrome
CN108434154A (zh) * 2013-10-25 2018-08-24 安泰赛普生物风投二代有限责任公司 用于治疗疾病的唑来膦酸或相关化合物的经口施用组合物

Also Published As

Publication number Publication date
CA2928350C (en) 2018-01-09
IL254123A0 (en) 2017-10-31
JP6166471B2 (ja) 2017-07-19
KR101975687B1 (ko) 2019-05-07
EP3060220A1 (en) 2016-08-31
CA2928350A1 (en) 2015-04-30
JP6453387B2 (ja) 2019-01-16
JP2024040304A (ja) 2024-03-25
JP2017200941A (ja) 2017-11-09
CN108434154A (zh) 2018-08-24
HK1257400A1 (zh) 2019-10-18
SG11201603042TA (en) 2016-05-30
KR20170058444A (ko) 2017-05-26
JP2021028343A (ja) 2021-02-25
WO2015060924A1 (en) 2015-04-30
KR101739244B1 (ko) 2017-05-23
SG10201609548UA (en) 2016-12-29
JP2019059771A (ja) 2019-04-18
EP3060220A4 (en) 2017-05-31
CN105960240B (zh) 2018-04-20
AU2014340649B2 (en) 2016-11-17
CN105960240A (zh) 2016-09-21
IL245287A0 (en) 2016-06-30
AU2017200832A1 (en) 2017-03-02
MY176246A (en) 2020-07-24
JP7136487B2 (ja) 2022-09-13
JP2016534081A (ja) 2016-11-04
KR20160062177A (ko) 2016-06-01
AU2014340649C1 (en) 2017-05-18
JP6802245B2 (ja) 2020-12-16
JP2022162105A (ja) 2022-10-21
SG10201800001VA (en) 2018-02-27
KR20190009428A (ko) 2019-01-28

Similar Documents

Publication Publication Date Title
MY176246A (en) Compositions for oral administration of zoledronic acid or related compounds for treating disease
NZ702414A (en) Compositions comprising zoledronic acid or related compounds for relieving inflammatory pain and related conditions
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
EA201890767A1 (ru) C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений
PH12016502352A1 (en) Pharmaceutical composition
PH12016501519B1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
PH12014502065A1 (en) Vesicular formulations
EA201591704A1 (ru) Новые устойчивые соли пентадекапептида, способ их получения, их применение в производстве фармацевтических составов и их применение в терапии
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica
MX368641B (es) Compuestos para el tratamiento de inflamación y dolor.
MX2014011520A (es) Administracion de eritoran o sales farmaceuticamente aceptables del mismo para tratar infecciones para ortomixovirus.
PH12015502703A1 (en) Pharmaceutical compositions
MX2016002139A (es) Composicion farmaceutica y uso del (2-cianoetil)fosfonato de dietilo.
PH12015502560A1 (en) Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease
MY196155A (en) Osteoclast Inhibitors for Pain